Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Twelve-month, Multicenter, Open-label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus With IL-2 Receptor Antagonist, Corticosteroids and Two Different Exposure Levels of Tacrolimus in de Novo Renal Transplant Recipients

NCT00369161 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00369161
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00369161 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Twelve-month, Multicenter, Open-label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus With IL-2 Receptor Antagonist, Corticosteroids and Two Different Exposure Levels of Tacrolimus in de Novo Renal Transplant Recipients
Lead sponsor
Novartis
Phase
Phase 4
Overall status
Completed
Start date
June 30, 2006
Completion date
December 31, 2008
Enrollment
228 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

renal transplantation